Suppr超能文献

度洛西汀:一种用于治疗抑郁症的新型5-羟色胺/去甲肾上腺素再摄取抑制剂。

Duloxetine: a new serotonin/noradrenaline reuptake inhibitor for the treatment of depression.

作者信息

Rabasseda Xavier

机构信息

Medical Information Department, Prous Science, Barcelona, Spain.

出版信息

Drugs Today (Barc). 2004 Sep;40(9):773-90. doi: 10.1358/dot.2004.40.9.850497.

Abstract

Double-blind, placebo-controlled clinical trials have evaluated and demonstrated the efficacy of duloxetine as an antidepressant in patients with major depressive disorders. The drug has been noted to be well tolerated and effective in the control of depressive symptoms. In addition, duloxetine has been shown to be better than placebo and as effective as paroxetine as an antidepressant and also better than placebo for reducing pain in both experimental models and patients. Duloxetine is a safe and well-tolerated new treatment option for depression including anxiety and painful physical symptoms. Furthermore, duloxetine has proven robust efficacy in stress urinary incontinence.

摘要

双盲、安慰剂对照临床试验已评估并证明度洛西汀作为抗抑郁药对重度抑郁症患者的疗效。该药物耐受性良好,对控制抑郁症状有效。此外,度洛西汀已被证明在抗抑郁方面优于安慰剂且与帕罗西汀效果相当,在实验模型和患者中减轻疼痛方面也优于安慰剂。度洛西汀是一种安全且耐受性良好的新型抑郁症治疗选择,包括焦虑和疼痛性躯体症状。此外,度洛西汀已在压力性尿失禁方面证明有强大疗效。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验